ACAD
Price
$21.34
Change
-$0.43 (-1.98%)
Updated
Jun 5 closing price
Capitalization
3.57B
54 days until earnings call
HRTX
Price
$2.00
Change
-$0.04 (-1.96%)
Updated
Jun 5 closing price
Capitalization
305.13M
67 days until earnings call
Interact to see
Advertisement

ACAD vs HRTX

Header iconACAD vs HRTX Comparison
Open Charts ACAD vs HRTXBanner chart's image
ACADIA Pharmaceuticals
Price$21.34
Change-$0.43 (-1.98%)
Volume$1.5M
Capitalization3.57B
Heron Therapeutics
Price$2.00
Change-$0.04 (-1.96%)
Volume$787.51K
Capitalization305.13M
ACAD vs HRTX Comparison Chart
Loading...
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HRTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACAD vs. HRTX commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACAD is a Hold and HRTX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (ACAD: $21.33 vs. HRTX: $2.00)
Brand notoriety: ACAD and HRTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACAD: 70% vs. HRTX: 50%
Market capitalization -- ACAD: $3.57B vs. HRTX: $305.13M
ACAD [@Biotechnology] is valued at $3.57B. HRTX’s [@Biotechnology] market capitalization is $305.13M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACAD’s FA Score shows that 1 FA rating(s) are green whileHRTX’s FA Score has 0 green FA rating(s).

  • ACAD’s FA Score: 1 green, 4 red.
  • HRTX’s FA Score: 0 green, 5 red.
According to our system of comparison, ACAD is a better buy in the long-term than HRTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACAD’s TA Score shows that 5 TA indicator(s) are bullish while HRTX’s TA Score has 5 bullish TA indicator(s).

  • ACAD’s TA Score: 5 bullish, 6 bearish.
  • HRTX’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, HRTX is a better buy in the short-term than ACAD.

Price Growth

ACAD (@Biotechnology) experienced а -4.31% price change this week, while HRTX (@Biotechnology) price change was +4.71% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.85%. For the same industry, the average monthly price growth was +10.46%, and the average quarterly price growth was -0.86%.

Reported Earning Dates

ACAD is expected to report earnings on Jul 30, 2025.

HRTX is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+7.85% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACAD($3.57B) has a higher market cap than HRTX($305M). HRTX YTD gains are higher at: 30.719 vs. ACAD (16.240). ACAD has higher annual earnings (EBITDA): 102M vs. HRTX (2.76M). ACAD has more cash in the bank: 682M vs. HRTX (50.7M). ACAD has less debt than HRTX: ACAD (56M) vs HRTX (177M). ACAD has higher revenues than HRTX: ACAD (996M) vs HRTX (149M).
ACADHRTXACAD / HRTX
Capitalization3.57B305M1,170%
EBITDA102M2.76M3,698%
Gain YTD16.24030.71953%
P/E Ratio15.57N/A-
Revenue996M149M668%
Total Cash682M50.7M1,345%
Total Debt56M177M32%
FUNDAMENTALS RATINGS
ACAD vs HRTX: Fundamental Ratings
ACAD
HRTX
OUTLOOK RATING
1..100
237
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
66
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
27100
PRICE GROWTH RATING
1..100
3761
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ACAD's Valuation (63) in the Biotechnology industry is in the same range as HRTX (66). This means that ACAD’s stock grew similarly to HRTX’s over the last 12 months.

ACAD's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as HRTX (100). This means that ACAD’s stock grew similarly to HRTX’s over the last 12 months.

ACAD's SMR Rating (27) in the Biotechnology industry is significantly better than the same rating for HRTX (100). This means that ACAD’s stock grew significantly faster than HRTX’s over the last 12 months.

ACAD's Price Growth Rating (37) in the Biotechnology industry is in the same range as HRTX (61). This means that ACAD’s stock grew similarly to HRTX’s over the last 12 months.

ACAD's P/E Growth Rating (100) in the Biotechnology industry is in the same range as HRTX (100). This means that ACAD’s stock grew similarly to HRTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACADHRTX
RSI
ODDS (%)
Bearish Trend 1 day ago
70%
Bullish Trend 1 day ago
87%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
66%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
68%
Bullish Trend 1 day ago
87%
MACD
ODDS (%)
Bearish Trend 1 day ago
62%
Bullish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
70%
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
85%
Advances
ODDS (%)
Bullish Trend 11 days ago
73%
Bullish Trend 3 days ago
83%
Declines
ODDS (%)
Bearish Trend 1 day ago
72%
Bearish Trend 15 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HRTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VTMGX18.02N/A
N/A
Vanguard Developed Markets Index Admiral
TMLCX36.39N/A
N/A
SEI Tax-Managed Large Cap F (SIMT)
GDSTX24.59N/A
N/A
Goldman Sachs Small Cap Eq Insghts Inv
BAUAX25.89N/A
N/A
Brown Advisory Small-Cap Fdmtl Val Adv
JSMVX16.97N/A
N/A
Jackson Square SMID-Cap Growth Inv

ACAD and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACAD has been loosely correlated with INZY. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ACAD jumps, then INZY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACAD
1D Price
Change %
ACAD100%
-2.02%
INZY - ACAD
50%
Loosely correlated
+0.25%
AURA - ACAD
45%
Loosely correlated
-0.57%
CRSP - ACAD
42%
Loosely correlated
+1.37%
PRME - ACAD
41%
Loosely correlated
+3.79%
PGEN - ACAD
40%
Loosely correlated
N/A
More

HRTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, HRTX has been loosely correlated with GSGTF. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if HRTX jumps, then GSGTF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HRTX
1D Price
Change %
HRTX100%
-1.96%
GSGTF - HRTX
45%
Loosely correlated
N/A
AMRN - HRTX
44%
Loosely correlated
-0.46%
ARDX - HRTX
38%
Loosely correlated
-1.63%
ACAD - HRTX
38%
Loosely correlated
-2.02%
AXON - HRTX
38%
Loosely correlated
+1.08%
More